Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19-NPR

A global study of nearly 44,000 found that the COVID-19 vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease. The study was conducted in the U.S., Latin America and South Africa. The vaccine did better at preventing disease in the U.S. – 72% — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%. The South African results are troubling because of the coronavirus variant spreading there that has now been detected in the U.S., raising concerns that the vaccines developed so far might not work as well against it. NPR, 01/29/2021

•   Print
•   Email
•   Share
•   Tweet